Immune profiling analysis of immune cell infiltrates in TME showed that there was no difference in any of the measured markers between responders versus non-responders to CTLA-4 blockade at the pretreatment time point, while an analysis of early on-treatment tumor biopsies revealed a significantly higher density of CD8+ T cells in responders than non-responders to CTLA-4 blockade. The gene discussed is CTLA4; the disease is neoplasm.